MARKET

VTGN

VTGN

VistaGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.410
0.000
0.00%
Opening 09:49 03/02 EST
OPEN
2.410
PREV CLOSE
2.410
HIGH
2.435
LOW
2.373
VOLUME
236.89K
TURNOVER
--
52 WEEK HIGH
3.180
52 WEEK LOW
0.3000
MARKET CAP
341.48M
P/E (TTM)
-8.9993
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Penny Stocks To Buy With Analysts Targeting 76%-209% Upside
Feb 24, 2021 (Penny Stocks via COMTEX) -- Analysts Are Bullish On These 4 Penny Stocks We've discussed penny stocks and analyst ratings many times before....
Penny Stocks · 5d ago
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 02/23 12:25
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation Alternatives to Current Standard of Care for Anxiety Disorders
Investor Brand Network · 02/22 15:33
AVGR, EBON, LODE and NXTD among midday movers
Gainers: Immunome (IMNM) +120%.Greenland Technologies (GTEC) +119%.Liberty TripAdvisor (LTRPB) +60%.Motus GI Holdings (MOTS) +35%.Charah Solutions (CHRA) +35%.Avinger (AVGR) +34%.VistaGen Therapeutics (VTGN) +32%.U.S. Well Services (USWS) +28%.Ebang Intern...
Seekingalpha · 02/18 17:40
Immunome, Avinger leads healthcare gainers; MEDNAX, ReWalk Robotics among major losers
Gainers: Immunome (IMNM) +93%, Avinger (AVGR) +33%, Titan Pharmaceuticals (TTNP) +17%, GBS (GBS) +15%, VistaGen Therapeutics (VTGN) +15%.Losers: MEDNAX (MD) -23%, ReWalk Robotics (RWLK) -21%, Shineco (TYHT) -19%, Check-Cap (CHEK) -15%, Advaxis (ADXS) -12%.
Seekingalpha · 02/18 16:01
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2021
Benzinga · 02/18 15:02
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation of Medicines with Potential to Treat Rising Mental Health Challenges from Depression
Mental health experts note growing concern over impact of COVID-19 on nation's mental health Compounding stress could have serious health, social...
Investor Brand Network · 02/18 14:25
Thinking about buying stock in Avinger, Rigel Pharmaceuticals, Vistagen Therapeutics, Bio-Path, or Corvus Pharmaceuticals?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVGR, RIGL, VTGN, BPTH, and CRVS.
PR Newswire - PRF · 02/18 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTGN. Analyze the recent business situations of VistaGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTGN stock price target is 5.67 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 67.48M
% Owned: 47.63%
Shares Outstanding: 141.69M
TypeInstitutionsShares
Increased
7
2.28M
New
33
61.67M
Decreased
5
100.27K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.73%
Pharmaceuticals & Medical Research
+0.18%
Key Executives
President/Chief Scientific Officer/Director
H. Snodgrass
Chairman/Independent Director
Jon Saxe
President/Founder/Chief Scientific Officer/Director
H. Ralph Snodgrass
Chief Executive Officer/Director
Shawn Singh
Chief Financial Officer/Vice President/Secretary
Jerrold Dotson
Senior Vice President
Mark Ginski
Vice President
Mark McPartland
Vice President
Louis Monti-Bloch
Other
Mark Smith
Independent Director
Ann Cunningham
Independent Director
Jerry Gin
Independent Director
Brian Underdown
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About VTGN
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). The company's pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. In addition, the Company has developed a human pluripotent stem cell (hPSC) technology platform, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs).

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.